PharmaEssentia Corporation (LUX:261280523)

Market Cap	12.70B +144.6%
Revenue (ttm)	474.57M +54.3%
Net Income	160.86M +52.1%
EPS	0.39 +51.8%
Shares Out	n/a
PE Ratio	78.97
Forward PE	41.32
Dividend	0.02 (0.08%)
Ex-Dividend Date	Jul 9, 2026

Volume	n/a
Open	n/a
Previous Close	35.60
Day's Range	n/a
52-Week Range	13.06 - 43.06
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and imm...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 131
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: 261280523

Financial Performance

In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.

Financial numbers in TWD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 26, 2026

Data Sources Report a data error